Latest Andrew Witty Stories
- Creates a new focused HIV business with the independence and sustainability to deliver significant improvements in treatment, access and shareholder value - Renews focus on HIV with industry-leading pipeline to deliver more new HIV treatments - Equity split of 85% GSK and 15% Pfizer LONDON and PHILADELPHIA, April 16 /PRNewswire-FirstCall/ -- GlaxoSmithKline plc (NYSE: GSK) and Pfizer Inc (NYSE: PFE) today announced they have entered into an agreement to create a new world-leading HIV...
According to the head of British pharmaceutical giant GlaxoSmithKline, the company will begin sharing knowledge of patented treatments, and will cut prices for medication in developing nations.
LONDON, February 5 /PRNewswire-FirstCall/ -- In a video interview Andrew Witty, GlaxoSmithKline CEO, described the pharmaceutical group's results as "robust" in a year that was "always going to be challenging". GSK also announced that it will cease providing EPS guidance, to allow a focus on longer term strategic goals. Describing 2008 as a strategic turning point for GSK Mr Witty said: "We started to make very clear what it would take to really make this company strong over the...
PHILADELPHIA, Jan. 29 /PRNewswire-FirstCall/ -- On Thursday, February 5th, GlaxoSmithKline plc (NYSE: GSK) will announce its year end financial results for the year ended December 31, 2008.
Biota Holdings Limited (ASX: BTA) today announced it had concluded its litigation against GlaxoSmithKline (GSK). The announcement followed formal mediation between by the parties ordered by the Victorian Supreme Court.
GlaxoSmithKline Plc continued its roll-out of new products on Wednesday, winning fresh regulatory approvals for two niche treatments to fight diabetes and cancer.
- A political dynamiter.